FGFR3 and urothelial carcinoma: In urothelial carcinoma, FGFR3 alterations have been previously documented in nearly 60% of low-grade noninvasive papillary urothelial carcinoma of the bladder, 35.6% of upper tract high-grade urothelial cancer, and 26.7% of overall urothelial carcinoma [30,31,32].